Cytori Therapeutics (NASDAQ: CYTX) is one of 91 publicly-traded companies in the “Medical Equipment, Supplies & Distribution” industry, but how does it compare to its rivals? We will compare Cytori Therapeutics to related businesses based on the strength of its analyst recommendations, profitability, earnings, institutional ownership, valuation, dividends and risk.
Insider and Institutional Ownership
11.8% of Cytori Therapeutics shares are held by institutional investors. Comparatively, 66.9% of shares of all “Medical Equipment, Supplies & Distribution” companies are held by institutional investors. 1.9% of Cytori Therapeutics shares are held by company insiders. Comparatively, 11.8% of shares of all “Medical Equipment, Supplies & Distribution” companies are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
This table compares Cytori Therapeutics and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Cytori Therapeutics Competitors||-124.64%||-36.13%||-9.58%|
Valuation & Earnings
This table compares Cytori Therapeutics and its rivals top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||NetIncome||Price/Earnings Ratio|
|Cytori Therapeutics||$4.66 million||-$22.04 million||-0.39|
|Cytori Therapeutics Competitors||$1.05 billion||$129.96 million||206.04|
Cytori Therapeutics’ rivals have higher revenue and earnings than Cytori Therapeutics. Cytori Therapeutics is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
Volatility and Risk
Cytori Therapeutics has a beta of 2.79, meaning that its share price is 179% more volatile than the S&P 500. Comparatively, Cytori Therapeutics’ rivals have a beta of 1.11, meaning that their average share price is 11% more volatile than the S&P 500.
This is a summary of recent ratings and recommmendations for Cytori Therapeutics and its rivals, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Cytori Therapeutics Competitors||197||1207||2643||92||2.64|
Cytori Therapeutics currently has a consensus price target of $3.65, suggesting a potential upside of 812.50%. As a group, “Medical Equipment, Supplies & Distribution” companies have a potential upside of 7.24%. Given Cytori Therapeutics’ higher possible upside, equities analysts plainly believe Cytori Therapeutics is more favorable than its rivals.
Cytori Therapeutics rivals beat Cytori Therapeutics on 10 of the 12 factors compared.
About Cytori Therapeutics
Cytori Therapeutics, Inc. (Cytori) is a biotechnology company engaged in the development of treatments and devices for a range of disorders using cells as a key part of the therapy. The Company develops cellular therapeutics formulated and optimized for specific diseases and medical conditions and related products. It is focused on developing primary product, Cytori Cell Therapy, for patients with scleroderma hand dysfunction, orthopedic disorders, cardiovascular disease, urinary incontinence and thermal burns, including those complicated by radiation. Its cellular therapeutics are collectively known by the name, Cytori Cell Therapy, which consists of a heterogeneous population of specialized cells, including stem cells that are involved in response to injury, repair and healing. These cells are extracted from an adult patient’s own adipose tissue using its automated, enzymatic, sterile Celution System devices and consumable sets at the place where the patient is receiving their care.
What are top analysts saying about Cytori Therapeutics Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Cytori Therapeutics Inc and related companies.